Psychedelic Supply Chain: New Business Models Anticipate Future Demand
Medical Cannabis And Ketamine Clinics Are Prepping The Market For New Psychedelic Products
Executive Summary
Prescription psychedelic drugs in development, and supply for the growing recreational and medicinal use markets globally, are creating new business opportunities in mental health.
You may also be interested in...
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Translating Psychedelic Experiences Into Targeted Health Outcomes: Optimism And Concern
A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.
Psychedelics For CNS Disorders: Understanding The Opportunity
Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.